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T
he potential therapeutic beneﬁt of allosteric modulation of
G-protein-coupled receptors (GPCRs) is increasingly being
recognized.
1,2Allostericmodulationcanbeanattractivemechan-
ism of action for GPCR drugs for several reasons. First, distinct
allosteric binding sites may be less conserved than orthosteric
sitesandthusoﬀerdiﬀerentselectivityproﬁles.Second,allosteric
and orthosteric ligands often occupy diﬀerent areas of chemical
space with diﬀerent physicochemical properties; thus, poten-
tially, an allosteric site may be more druggable. Third, allosteric
ligands do not directly compete with the endogenous agonists;
therefore, they may exhibit insurmountable kinetics and thus
oﬀer the possibility of lower drug doses or prolonged pharma-
codynamic proﬁles. Fourth, allosteric ligands may oﬀer the
possibility of modulating pharmacology by exhibiting coopera-
tivitywithorthostericligandsorselectivelymodulatingthesignal
from an orthosteric ligand.
However, the discovery of allosteric ligands can be challenging
with conventional GPCR assay formats. Some allosteric antago-
nists are known to disrupt agonist signaling without necessarily
disrupting the binding of the agonist to the receptor. Competitive
displacement assays with an endogenous ligand may fail to detect
thebindingofanoncompetitiveligandtoanovelbindingsite.The
use of radiolabeled ligands in displacement assays also introduces
expensivemanufacturinganddisposalcosts.Allostericmodulators
can also exhibit “probe dependence”. For example, the CCR5
antagonist, aplaviroc, blocks the binding of
125I-MIP-1R but not
125I-RANTES; thus, a radioligand displace screen with
125I-
RANTES would have failed to ﬁnd this compound.
3 Ar a n g eo f
probe dependencies have been observed for synthetic CCR5
ligands: from compounds that block chemokine binding but not
HIV-1gp-120binding
4tocompoundsthatblockHIV-1bindingbut
partially spare CCR5 function through chemokine signaling.
5
To overcome some of these issues with displacement assays,
indirect signaling assays are commonly used in drug discovery,
wherethedownstreamresponseofasignalingpathwayisusedto
detect functional binding to a receptor. Common receptor
signaling assay formats include ﬂuorescence-based systems that
detect levels of calcium (Ca
2þ) mobilization, cyclic adenosine
monophosphate(cAMP),inositolphosphates(IP1andIP3),and
ERK signaling. Functional assays are often unable to distinguish
between diﬀerent mechanisms without more detailed deconvo-
lution and displacement assays. Small molecule synthetic ligands
mayevenmimicthefunctionof endogenous agonists.Theinitial
high-throughout screening hit(UK-107,543) that wasoptimized
into the drug maraviroc is a small molecule agonist of CCR5
discovered by the screening of the displacement of radiolabeled
MIP-1β.
4,6 Modiﬁcation of the agonist UK-107,543 resulted in
compounds that are antagonists. However, despite their wide-
spread use, signiﬁcant limitations of indirect signaling-based
assays are emerging, as ligands can possess “functional
selectivity”,
7wherealigandcaninducediﬀerentialsignalstoward
diﬀerent pathways. Thus, the “eﬃcacy” of a GPCR ligand
complex is dependent on the context of the downstream
components present in a cell type
8 where a ligand can demon-
stratedualandoppositeeﬃcaciesondiﬀerentsignalingpathways
while binding to the same target: That is, the same compounds
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ABSTRACT: G-protein coupled receptors (GPCRs) are a class of
drug targets of primary importance. However, receptor assays are
basedonmeasurementofeitherliganddisplacementordownstream
functional responses, rather than direct observation of ligand bind-
ing. Issues of allosteric modulation, probe dependence, and func-
tional selectivity create challenges in selecting suitable assays
formats. Therefore, a method that directly measures GPCR ligand
interactions, independent of binding site, probe, and signaling
pathway would be a useful primary and orthogonal screening method. We have developed a GPCR biosensor assay protocol
that oﬀers the opportunity for high-throughput label-free screening that directly measures GPCR ligand interactions. The
biosensor-based direct screening method identiﬁes the interaction of both orthosteric and allosteric ligands with solubilized, native
GPCRs, in a label-free and cell-free environment, thus overcoming the limitations of indirect and displacement assay methods. We
exemplify the method by the discovery of novel ligands for the chemokine receptor, CCR5, that are ligand eﬃcient fragments.
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can be an agonist against one pathway but an antagonist or
inverse agonist against another pathway.
9 These caveats suggest
thatsomesignalingassaysmightnotdetect allosteric modulators
if only one signaling pathway is measured. The binding of some
allostericligandsmaymodulatereceptorinternalizationandthus
also fail to be detected by many functional assays and indirect
signaling screens.
A further complication is the putative intracellular location of
several newly discovered allosteric binding sites, which may
remain undetected in cell-based assays, if novel, unoptimized
compounds do not possess the necessary physicochemical
properties to permeate the cell membrane or the choice of cell
type possesses pumps and transporters that lower the eﬀective
intracellular concentration of the compounds.
10,11
The phenomena of allosteric modulation, probe dependence,
and functional selectivity create possibilities for sophisticated
pharmacology for novel GPCR drugs. However, these aspects
also highlight some severe limitation with current GPCR screen-
ing formats. Therefore, there is a need for direct binding assays
forGPCRsthatcandistinguishbetweenbindingandfunction,as
function is often context dependent. A method that directly
measures GPCR ligand interactions, independent of binding
site or signaling pathway, would be useful means of conﬁrming
high-throughput screening (HTS) hits and potentially a primary
screening method in its own right.
Surface plasmon resonance (SPR) is emerging as an analysis
method to determine the kinetics and aﬃnity of protein, peptide,
and small molecule ligands with GPCRs.
4,12 16 SPR has several
advantages as a biophysical method for measuring GPCR ligand
interactions. First, SPR is a “label-free” method that measures the
direct binding of a ligand with the receptor. Second, SPR analysis
occurs in real time and thus enables association and dissociation
r a t e st ob em e a s u r e dt od e t e r m i n ek i n e t i c sa n da ﬃnity. Third, SPR
has been applied to both puriﬁed, thermostabilized receptors
15,16
and native-tagged receptors captured directly from cell pellets.
12 14
Here,wedescribethedevelopmentofSPRintoaprimaryscreening
methodology for tagged, native GPCRs to discover novel ligands
for CCR5.
The class A GPCR, chemokine receptor type 5 (CCR5),
modulates several inﬂammatory mechanisms through the bind-
ing of the chemokines macrophage inﬂammatory protein (MIP)
1R (CCL3), MIP-1β (CCL4), and RANTES (CCL5). CCR5 is
an important therapeutic target as it is the major coreceptor, in
cooperation with CD4, for the cell entry of HIV role. The CCR5
antagonist, maraviroc, is an approved drug for the treatment of
HIV-1. Maraviroc
17 and many other chemokine antagonists are
noncompetitive allosteric inhibitors respective to the orthosteric
chemokine agonists.
3
Previously, we have described the kinetic analysis of the
chemokines RANTES
14 and the small molecules TAK 779
14
Figure 1. (A) Assay design: 1D4 mAb is immobilized on the dextran surface of the CM4 chip, CCR5 is captured on spots 1 and 5, and maraviroc is
injected onspot5onlyto blockthe activesiteofCCR5. (B)Sensorgramscollected onsurfaces: activeCCR5, 1D4surface, andblockedCCR5.Binding
ofcontrolcompoundUK-107543at3-foldconcentrationseries0.0045 10μMandoverlayofpositive(UK-107543)andnegative(sulpiride)controlat
5 μM injected during screen.551 dx.doi.org/10.1021/ml2000017 |ACS Med. Chem. Lett. 2011, 2, 549–554
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and maraviroc
4 with CCR5 using SPR. In this study, we extend the
SPR analysis of GPCRs into a screening method for immobilized
CCR5. A Bayesian activity model for CCR5 was used to select 200
compoundsfromtheUniversityofDundee'scompoundﬁleofover
90000 compounds, the vast majority of which are purchased from
commercial suppliers (see the Supporting Information). The
Bayesian activity model was trained using 1166 known CCR5
ligands from 206748 compounds in the ChEMBL database
(version 2). Chemical structure information was described as
extended connectivity ﬁngerprints (ECFP) with a neighborhood
size of 6.
We used a previously developed CCR5 SPR assay
12 14 where
wecapturedC9-taggednativeCCR5receptor onthesensorchip
of Biacore 4000 instrument. The Biacore 4000 ﬂuidics system
allows the assignment of ﬁve detection spots to each of four ﬂow
cells, enabling the screening of four diﬀerent compounds per
cycle,whereoneofthetargetsperﬂowcellhastobeassignedasa
reference or preferably left blank. In our case, we immobilized
1D4 antibody on all detection spots of all four ﬂow cells and
capturedsolubilizednativeCCR5viaC-terminalC9tagontotwo
spots of each ﬂow cell, leaving three spots per ﬂow cell as
reference with immobilized 1D4 mAb (Figure 1A). By solubiliz-
ing membrane proteins from native membranes, it is not always
possible to obtain 100% active receptor captured on the sensor
surface, therefore leaving some proportion of the receptor
inactive or containing residuals from membrane attached to
the receptor. All of these factors can contribute to a nonspeciﬁc
binding when screening libraries of compounds that can act as
false positives, mainly at high concentrations. Therefore, it is
important, especially for membrane proteins, to ﬁnd the closest
reference target as possible. Suitable reference systems could be
(i) unrelated membrane proteins that are solubilized and cap-
tured in the same way as target protein; (ii) deactivated mem-
brane proteins, solubilized in detergent, which will solubilize
receptor from the membrane, but does not keep active con-
formation; or (iii) receptors with binding sites that have been
blocked with known high aﬃnity ligands. Because the vast
majority of CCR5 ligands used to train the Bayesian model that
isusedtoselectthescreeninglibraryarelikelytobindtothesame
siteasmaraviroc,wethereforeusedCCR5receptorblockedwith
5 μM maraviroc as a reference. Maraviroc binds to CCR5 with
high aﬃnity (KD = 25 nM) and dissociates very slowly from the
receptor (oﬀ-rate, kd =6  10
 4 s
 1).
4 To keep the receptor
blocked during screening and follow up conﬁrmation experi-
ment, we repeated injections of 5 μM maraviroc every 10 cycles,
addressing the injection only over reference spot, while leaving
activeCCR5intact.Totesttheactivityofthereceptorandalsoto
distinguish between speciﬁc and nonspeciﬁc binding sensor-
grams,weincludedinjectionsofnegative(sulpiride)andpositive
(UK-107,543)
4 control at a 5 μM concentration within the
screen. Figure 1B shows concentration series of control com-
pound and overlay of binding sensorgrams for both positive and
negative controls to active CCR5, reference surface with im-
mobilized 1D4 mAb, and CCR5 blocked with maraviroc during
one experimental run collected on one of four ﬂow cells.
Negative control sulpiride does not show any binding to any of
the surfaces. The positive control shows concentration-depen-
dent binding to active CCR5 with a slow oﬀ-rate (in red circle).
Bindingofthepositivecontroltoblockedreceptoroccursonlyat
high concentrations and fast oﬀ-rate, suggesting that the binding
is either weak or nonspeciﬁc. A clear diﬀerence in the binding
modes for control compound to active and blocked CCR5
suggests this compound to be a suitable control to assess the
validity of the assay and activity of receptor during the screen.
Eachcompoundwasscreenedatthreeconcentrations:0.1,1,and
10 μM. The overlay of binding sensorgrams is shown in the
Supporting Information, Figure 1, together with report points
read just before the end of injection for each analyte. Most of the
compounds show responses at the highest concentrations for
both active and blocked receptors, therefore identifying binders
based only on the response in equilibrium is not a suitable
method to distinguish between true and nonspeciﬁc ligands.
Each sensorgram was therefore carefully inspected, and only
compounds showing diﬀerences for binding modes between
active and blocked receptor were selected for further conﬁrma-
tion. Hit conﬁrmation was run in 3-fold concentration series at
0.3 25 μM. All concentrations were injected in duplicate and
referenced for 1D4 mAb surface and blank injections of buﬀer to
minimize nonspeciﬁc signal and possible baseline drift. A total of
ﬁvehitsintwochemicalserieswereidentiﬁedasbinderstoactive
form of CCR5 (Table 1). Sensorgrams and equilibrium ﬁts for
bothactiveandblockedCCR5areshowninFigure2.Theﬁvehit
Table 1. Chemical Structure, Aﬃnity and Ligand Eﬃciency (LE) of Ligands Binding to Maraviroc Pocket of CCR5 (Compounds
A E) and an Allosteric Pocket of CCR5 (Compounds F and G)
*Aﬃnity and LE measured to blocked CCR5.552 dx.doi.org/10.1021/ml2000017 |ACS Med. Chem. Lett. 2011, 2, 549–554
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compounds were counter-screened on the Biacore T100 against
CXCR4 using our previously described SPR assay.
12 14 Except
compound A, most of the compounds showed some response to
blocked CCR5 at higher concentrations. At the highest concen-
tration only, the ﬁve compounds also showed a small response
against CXCR4 (Supporting Information, Figure 2). We ob-
servedtheconﬁrmedhitscanbeclassiﬁedintotwodistinctchemical
series:compoundsA D,consistingofoneseries,andcompoundE,
representing second series. The ligand eﬃciencies (LE) for the hits
are 0.24 0.335 kcal/mol/nonhydrogen atoms with an average
Figure 2. Sensorgrams for compounds A E identiﬁed as hits binding to active and blocked CCR5. Each compound is injected in duplicate at 3-fold
concentration series 0.3 25 μM. Equilibrium ﬁts for aﬃnity determination are shown as an overlay for all compounds binding to both active and
blocked CCR5.
Figure 3. Binding responses for allosteric compounds F and G binding to active and blocked CCR5 and overlay of aﬃnity ﬁts for both compounds
binding to active and blocked CCR5. Compounds were injected in duplicates at 3-fold dilutions and concentrations of 1.23 33.3 μM (compound F)
and 1.23 100 μM (compound G).553 dx.doi.org/10.1021/ml2000017 |ACS Med. Chem. Lett. 2011, 2, 549–554
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LE = 0.282. The best LE was measured for compound A (KD =
10 μM, LE = 0.335). The LE of maraviroc is 0.275 due to its high
molecular mass(MW= 514Da). Interestingly,theaveragenumber
of heavy atoms for compounds A E is 23; therefore, the ratio of
heavy atoms for maraviroc [37 nonhydrogen (“heavy”)a t o m s ]t o
the average hit is 1.6. The ratio of average heavy atoms of hits (23
heavy atoms) to the additional structure required for a potent
compound(14heavyatoms)isalso1.6.Theratioof1.6issigniﬁcant
as it is the Golden Ratio. An analysis of a number of fragment
optimization projects reveals the ratio of the initial fragment to the
ﬁnalpotentcompoundisusuallytheGoldenRatio.
18Therefore,the
hit compounds A E can be considered as “fragment” ligands for
CCR5 according to the golden ratio argument. Aﬃnities, LE, and
BayesianpredictionrankingaresummarizedinTable1.Compound
A has the highest Bayesian prediction of all of the conﬁrmed hits.
Site-directed mutagenesis studies on CCR1,
19 CCR3,
20 and
CCR5
21 have revealed a common binding pocket formed by the
trans-membrane helices and exposed to the extracellular surface,
equivalent to the rhodopsin binding site. However, a number of
chemokine receptor antagonists and inverse agonists belong to
distinct chemical classes, and evidence suggests that these may bind
to distinct allosteric sites. To determine whether SPR is a suitable
method to detect the binding of compounds to distinct allosteric
bindingsitesonmembraneproteins,weincludedcompoundsFand
Ginthescreeninglibrary.ThepyrazinylsulfonamidescompoundsF
and G are allosteric CCR4 antagonists that are reported to be weak
CCR5 ligands.
10 Compounds were injected at 3-fold concentration
series 1.2 100 μM over both active and blocked CCR5. Interest-
ingly, compounds F and G showed approximately a 2-fold higher
response values (Rmax) when binding to blocked CCR5 over active
CCR5,suggestingthatmaravirocstabilizesCCR5inaconformation
thatbeneﬁtsthebindingofcompoundstotheintracellularallosteric
binding site
10 (Figure 3). The aﬃnities of compounds F and G
(Table1) areapproximatelyequivalentinthepresenceandabsence
of maraviroc.
We have developed a GPCR biosensor assay protocol for the
Biacore 4000 platform that oﬀers the opportunity for high-
throughput label-free screens that directly measure GPCR 
ligand interactions, independent of binding site. A biosensor-
based direct screening method to identify interactions between
orthosteric and allosteric ligands and solubilized GPCRs, in a
label-freeandcell-freeenvironment,overcomesthelimitationsof
indirect assay methods. A key advantage of the method is that it
utilizes native GPCR sequences and thus does not require
extensive protein engineering that is required for other more
expensive and labor-intensive biophysical methods such as X-ray
crystallography. The method that we have described can be a
useful tool for conﬁrming the binding and mode of action of hits
from cell-based screens and a primary screening method in its
own right for focused and fragment-like libraries.
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